Thrombosis and anticoagulation in palliative care: An evolving clinical challenge

Journal of Palliative Care

Volumn 20, Issue 2, 2004, Pages 101-104

  Kirkova, Jordanka ^a   Fainsinger, Robin L ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE COURSE; FAMILY; HEALTH STATUS; HUMAN; PALLIATIVE THERAPY; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; THROMBOSIS; TREATMENT PLANNING;

EID: 3242664559     PISSN: 08258597     EISSN: None     Source Type: Journal    
DOI: 10.1177/082585970402000206     Document Type: Review

References (32)

1. Walsh-McMonagle D, Green D. Low molecular weight heparin in the management of Trousseau's syndrome. Cancer 1997; 80(4): 649-655.
2. Hirsh J, Lee AYY. How we diagnose and treat deep vein thrombosis. Blood 2002; 99(9): 3102-3110.
3. Sarasin F, Eckman M. Management and prevention of thromboembolic events in patients with cancer related hypercoagulable states. J Gen Intern Med 1993; 9: 476-486.
4. Johnson MJ, Sherry K. How do palliative physicians manage thromboembolism? Palliat Med 1997; 11(6): 462-468.
5. VonDepka Prondzinski M, Karthaus M, Ganser A, Barthels M. Anticoagulant prophylaxis and therapy in patients with cancer. Antibiot Chemother 2000; 50: 149-158.
6. Chan A, Woodruff RK. Complications and failure of anticoagulation therapy in the treatment of venous thromboembolism in patients with disseminated malignancy. Aust N Z J Med 1992; 22: 119-122.
7. Johnson MJ. Problems of anticoagulation within a palliative care setting: an audit of hospice patients taking warfarin. Palliat Med 1997; 11(4): 306-312.
8. Douketis J, Foster G, Crowther A, Prins M, Ginsberg S. Clinical risk factors and timing of recurrent venous thromboembolism during the initial three months of anticoagulant therapy. Arch Intern Med 2000; 160: 3431-3436.
9. Merminod T, Zulian GB. Diagnosis of venous thromboembolism in cancer patients receiving palliative care. J Pain Symptom Manage 2000; 19(4): 238-239.
10. Meyer G, Marijanovich Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer. Arch Intern Med 2002; 162: 1729-1735.
11. Johnson MG, Sproule MW, Paul J. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer. Clin Oncol 1999; 11: 105-110.
12. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Buller HR. Incidence of recurrent and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved INR - a retrospective analysis. J Clin Oncol 2000; 18: 3078-3083.
13. Kakkar A, Williamson R. Prevention of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25(2): 239-243.
14. Rassmussen M. Preventing thromboembolic complications in cancer patients after surgery - a role for prolonged thromboprophylaxis. Cancer Treat Rev 2002; 28: 141-144.
15. Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA Jr, Wheeler HB. Prevention of venous thromboembolism. Chest 2001; 119 (suppl 1): 132S-175S.
16. Levine M, Hirsh J, Gent M, Arnold A, Warr D, Falanga A, et al. Double-blind randomised trial of very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer. Lancet 1994; 343: 886-889.
17. Moussa S. The low-molecular-weight heparin tinzaparin in thrombosis and beyond. Cardiovasc Drug Rev 2002; 20(3): 163-180.
18. Arkel YS. Thrombosis and cancer. Semin Oncol 2000; 27(3): 362-374.
19. Johnson MJ. Bleeding, clotting and cancer. Clin Oncol 1997; 9: 294-301.
20. Godwin J. Use of low-molecular-weight heparin in malignancy. Thromb Haemost 1996; 2: S28-S34.
21. Ellis SN, Boggs HW, Slagle GW, Cole PA, Coyle DJ, Blakemore WS. Protein C activity, stage of disease, and vascular thrombosis in colon carcinoma. Am J Surg 1992; 163: 78-81.
22. ten Wolde M, Kraaijenhagen RA, Prins MH, Buller HR. The clinical usefulness of D-dimer testing in cancer patients with suspected deep venous thrombosis. Arch Intern Med 2002; 162: 1880-1884.
23. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-1641.
24. Johnson MG, Walker ID, Sproule MW, Conkie J. Abnormal coagulation and deep venous thrombosis in patients with advanced cancer. Clin Lab Haematol 1999; 21: 51-54.
25. Bonar D, Hickey AD, Wallace DM. Efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost 1997; 8: 137-140.
26. Gitter MJ, Jaeger TM, Petterson TM, Gersh BJ, Silverstein MD. Bleeding and thromboembolism during anticoagulant therapy: a population-based study in Rochester, Minnesota. Mayo Clin Proc 1995; 70: 725-733.
27. Zacharski LR, Orstein DL, Mamourian AC. Low-molecular-weight heparin and cancer. Semin Thromb Hemost 2000; 26(suppl 1): 69-77.
28. Levine MN. Managing thromboembolic diseases in the cancer patients: efficacy and safety of antithrombotic treatment options in patients with cancer. Cancer Treat Rev 2002; 28: 145-149.
29. Smonenburg SM, Hutten B, Prins M. Should patients with cancer be treated differently. Haemostasis 1999; 29(1): 91-97.
30. Luk C, Wells P, Anderson D, Kovacs M. Extended outpatient therapy with low molecular heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. Am J Med 2001; 111: 270-273.
31. Schwarz R, Marrero A, Conlon, Burt M. Inferior vena cava filters in cancer patients-indications and outcome. J Clin Oncol 1996; 14(2): 652-657.
32. Marcy PY, Magne N, Gallard JC, Bondiau PY, Frenay M, Descamps B. Cost-benefit assessment of inferior vena cava filter placement in advanced cancer patients. Support Care Cancer 2002; 10: 76-80.